Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
IPO Year: 2018
Exchange: NASDAQ
Website: liquidia.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $13.00 | Perform → Underperform | Oppenheimer |
| 12/20/2024 | $20.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/19/2024 | Outperform → Strong Buy | Raymond James | |
| 8/16/2024 | $27.00 | Outperform | Raymond James |
| 6/25/2024 | Perform | Oppenheimer | |
| 1/5/2024 | $18.00 → $28.00 | Buy | Needham |
| 9/19/2022 | $3.00 | Underperform | Wedbush |
| 9/1/2022 | $3.00 | Neutral → Underperform | Wedbush |
| 7/22/2022 | $15.00 | Buy | Ladenburg Thalmann |